EP: 3. Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines EP: 4. Diagnosing IgA Nephropathy EP: 5. Signs and Symptoms of IgA Nephropathy EP: 6.

EP: 3. Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines EP: 4. Diagnosing IgA Nephropathy EP: 5. Signs and Symptoms of IgA Nephropathy EP: 6.

NephCure, a nonprofit organization focused on rare, protein-spilling kidney diseases, announced IgA Nephropathy Awareness Day, Sept. 26, to promote early diagnosis and treatment of the disease ...

In this video, Ali Poyan Mehr, MD, Regional Director of the Glomerular Disease Program at Kaiser Permanente Northern California, discusses the major risk factors for IgA nephropathy.

IgA nephropathy is a progressive, autoimmune, chronic kidney disease that can lead to end-stage kidney disease (ESKD) over the lifetime of most patients. 1,2,3,4 Otsuka was previously granted ...

For more information about IgA nephropathy and the role of APRIL, consider signing up to receive additional news and insights about IgA nephropathy at igancascade.com. October 2024 21US24EUP0096 ...

In patients with IgA nephropathy, elevated proteinuria and progression to kidney failure both increase the risk for cardiovascular events and early death, according to new real-world data ...

One study found that after 10 years, IgA nephropathy came back in 19% of those who had a kidney transplant. About 4 out of 10 (40%) transplanted kidneys in people with IgA nephrology eventually fail.

For IgA nephropathy, those numbers are difficult to achieve. Though common compared to other forms of kidney disease related to the immune system, IgA nephropathy is hard to diagnose, and ...

IgA nephropathy can be challenging, but a support system makes it easier to manage. Learn how to take steps to stay connected to your community when dealing with this disease.

The researchers with the Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study report recruitment for the multicenter, double-blind, placebo-controlled study, which aimed to ...